Received grant in 2019
DCCC has funded 200,000 DKK to the project.
Up to one-third recur after treatment for colorectal cancer. Circulating tumor DNA (ctDNA) in blood detects recurrence up to 16 months before standard radiological surveillance. IMPROVE IT2 is the world's first randomized trial comparing a personalized radiological surveillance guided by longitudinal ctDNA analysis to current one-sizefits all radiological surveillance. With a paradigm shift to ctDNA guided surveillance, we aim at early detection of recurrence allowing curative treatment, improved survival and efficient re-allocation of resources without compromising quality of life.
Multidisciplinary organisation
DCCG – Danish Colorectal Cancer Group
Project stakeholders
- Ass. Professor Kåre Gotschalck Sunesen, Dept. of Surgery, Regional Hospital, Randers. Primary contact, Mail: kaarsune@rm.dk
- Professor Claus Lindbjerg Andersen, Dept. of Molecular Medicine, Aarhus University Hospital
- Professor Lene Hjerrild Iversen, Dept. of Surgery, Aarhus University Hospital
- Professor Søren Laurberg, Dept. of Clinical Medicine, Aarhus University
- Professor Karen-Lise Garm Spindler, Dept. of Oncology, Aarhus University Hospital
- Professor Ole Thorlassius-Ussing, Dept. of Surgery, Aalborg University Hospital
- Professor Morten Ladekarl, Dept. of Oncology, Aalborg University Hospital
- Per Vadgaard Andersen, Dept. of Surgery, Odense University Hospital and Svendborg Hospital
- Professor Per Pfeiffer, Dept. of Oncology, Odense University Hospital
- Ass. Professor Anders Husted Madsen, Dept. of Surgery, Regional Hospital, Herning
- Uffe Schou Løve, Dept. of Surgery, Regional Hospital, Viborg
- Professor Ismail Gögenur, Center for Surgical Science, Zealand University Hospital (Køge, Slagelse and Roskilde Hospitals)
- Stine Kramer, Dept. of Nuclear Medicine & PET-Centre, Aarhus University Hospital
- Professor Jes Søgaard, Danish Centre for Health Economics, University of Southern Denmark